35 clinical trials matched your search for Bladder Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Bladder Cancer ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder Christopher Anderson, MD
Bladder Cancer Study of Intravesical Cabazitaxel, Gemcitabine and Cisplatin (CGC) in the Treatment of Urothelial Carcinoma (Bladder Cancer) Joel DeCastro, MD, MPH
Bladder Cancer First-in-Human Study of PF-07225570 Alone or in Combination with Sasanlimab for Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Joel DeCastro, MD, MPH
Cancer Identification of Targets for Cancer Treatment Andrea Califano, PhD
Cancer Study of Drug (MK-2118) in Patients with Solid Tumors or Lymphomas Matthew Ingham, MD
Cancer Study of IDE196 in Patients with Solid Tumors Richard Carvajal, MD
Cancer Study of BA3011 in Subjects with Advanced Solid Tumors Matthew Ingham, MD
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Brian Henick, MD
Cancer A Study in Subjects With Advanced Cancer Richard Carvajal, MD
Cancer TCR-engineered T Cells in Solid Tumors (ACTengine) Ran Reshef, MD
Cancer Smartphone App for Cancer Medication Adherence Melissa Accordino, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Richard Carvajal, MD
Cancer Study of RTX-240 in Adults with Relapsed/Refractory or Locally Advanced Solid Tumors Mark Stein, MD
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers Benjamin Izar, MD
Cancer Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer Bret Taback, MD
Cancer A Study of ASP9801 in Patients With Advanced Metastatic Solid Tumors Matthew Ingham, MD
Cancer Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Autoimmune Disorders Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Cancer COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors Benjamin Izar, MD
Cancer A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Cancer Benjamin Izar, MD
Cancer Study of BAY 1895344 in Combination with Chemotherapy for Patients with Advanced Cancer Mark Stein, MD
Cancer Study of New Oral Anti-Cancer Drug (OACD) Dawn Hershman, MD
Cancer First-in-Human Study of DS-7300a in Subjects with Advanced Cancer Mark Stein, MD
Cancer Study of MPT-0118 Alone or in Combination with Keytruda in Patients with Advanced or Metastatic Cancer Shaheer Khan, DO
Cancer Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses Dawn Hershman, MD
Cancer Study of INCB106385 Alone or in Combination with INCMGA00012 in Patients with Advanced Cancer Mark Stein, MD
Lung Cancer Study of Atezolizumab and Tiragolumab Alone or in Combination with Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of Ulixertinib (BVD-523) for Patients with Advanced Cancer that Show Genetic Alterations Richard Carvajal, MD
Cancer Study of PF-07263689 Alone or in Combination with Sasanlimab for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of RP-6306 in Combination with Gemcitabine (Chemotherapy) for Patients with Advanced Solid Tumors Ryan Moy, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Richard Carvajal, MD
Cancer Study of BT7480 in Patients with Advanced Cancer Richard Carvajal, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD